Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zentalis Pharmaceuticals
Biotech
ESMO: Why Zentalis is already dreaming of launching WEE1 drug
Zentalis pointed to the overall survival analysis for azenosertib as proof the WEE1 inhibitor offers a convenient oral treatment for a tricky cancer.
James Waldron
Oct 23, 2026 10:15am
Sanofi snags CMO from BioMarin—Chutes & Ladders
Aug 29, 2025 8:30am
Zentalis lays off 40% to fund registrational trial of WEE1 drug
Jan 29, 2025 4:42am
Flagship-backed biotechs name new leaders—Chutes & Ladders
Nov 15, 2024 8:30am
FDA places hold on Zentalis’ WEE1 drug after two sepsis deaths
Jun 18, 2024 8:21am
FDA's Peter Marks doesn't plan to retire soon—Chutes & Ladders
Aug 4, 2023 9:30am
